PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 1, 2025BMC Infectious Diseases4 citationsOpen Access

Modeling COVID-19 pneumonia and COVID-associated pulmonary aspergillosis: sensitivity analysis and optimal control

View Full Paper
MRMallela Ankamma RaoVignan's Foundation for Science, Technology & ResearchEJEmad K. JaradatImam Mohammad ibn Saud Islamic UniversityMDM DeviManipur University

Key Points

  • The combined application of vaccination, early hospitalisation, and enhanced treatment significantly reduces COVID-19 pneumonia and CAPA prevalence, improving public health outcomes.
  • Sensitivity indices reveal key parameters influencing transmission and severity, making targeted interventions feasible and effective in controlling COVID-19 complications.
  • The novel compartmental model integrates disease progression pathways and hospitalisation processes for COVID-19 and CAPA, addressing limitations of previous models.
  • Optimal control strategies derived from the model demonstrate cost-effectiveness of combined interventions within realistic constraints for healthcare systems.

Abstract

Severe cases of COVID-19 can progress to pneumonia and, in some patients, to COVID-19-associated pulmonary aspergillosis (CAPA), a fungal co-infection linked to high mortality. Most existing models address COVID-19 transmission alone, without explicitly capturing the sequential progression to pneumonia and CAPA. To address this gap, we develop a novel compartmental model (SIIcpIcaHR) that integrates the co-dynamics of COVID-19 pneumonia and CAPA, incorporating both disease progression pathways and hospitalisation processes. The model is calibrated using cumulative COVID-19 case data from India, and analysed through stability theory, sensitivity analysis, and an optimal control framework. Sensitivity indices and Partial Rank Correlation Coefficients identify key parameters influencing transmission and severity. We evaluate time-dependent intervention strategies—vaccination, early hospitalisation, and enhanced treatment—individually and in combination, using Pontryagin's Maximum Principle and numerical simulation. Results show that while each single measure reduces disease burden, combined application of all three significantly minimises pneumonia and CAPA prevalence, lowers hospitalisation needs, and is cost-effective within realistic constraints. These findings emphasise the importance of integrated public health strategies that couple pharmaceutical and clinical interventions to curb severe COVID-19 outcomes and associated fungal complications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rao et al. (2025) studied this question.

synapsesocial.com/papers/68dd89e6fe798ba2fc498262https://doi.org/10.1186/s12879-025-11606-x
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predicting COVID 19–Associated Pulmonary Aspergillosis Risk in Low- and Middle-Income Countries: A Matched Case-Control Study2024 · 1 citations
  2. 2Fractional optimal control and cost-effective analysis of community-acquired pneumonia2025
  3. 3COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants2024 · 6 citations
  4. 4Pulmonary Tuberculosis and Pneumonia Co-Dynamics: A Mathematical Modelling Approach2025
  5. 5Clinical characteristics and predictive models for hospitalized patients with COVID-19 combined with bacterial pneumonia2025